US2021070832A1PendingUtilityA1
Antigen-specific helper t-cell receptor genes
Assignee: INT INST CANCER IMMUNOLOGY INCPriority: Sep 12, 2012Filed: Oct 22, 2020Published: Mar 11, 2021
Est. expirySep 12, 2032(~6.1 yrs left)· nominal 20-yr term from priority
A61K 40/4243A61K 40/32A61K 40/11A61K 2239/48A61K 2239/31A61K 2239/38C12N 5/0636A61K 38/1774A61K 35/17C07K 16/2809G01N 33/56972C12Q 1/6886C12Q 1/6881C07K 16/28C07K 14/7051A61P 35/00C12Q 2600/158C12N 2510/00G01N 2333/70514G01N 2333/4703A61K 38/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention pertains to polynucleotides that encode CDR3 in TCR-[alpha] and TCR-[beta] chain genes of CD4+ helper T-cells that are specific to WT1 helper peptides having an amino acid sequence represented by SEQ ID NO: 123. The present invention further pertains to the peptides encoded by said polynucleotides. The present invention further pertains to CD4+ T cells into which TCR genes that contain said polynucleotides have been introduced, the induction of WT1-specific cytotoxic T-lymphocytes (CTLs) using the CD4+ T-cells, the treatment of cancer, etc.
Claims
exact text as granted — not AI-modified1 - 22 . (canceled)
23 . An αCDR3 peptide encoded by a polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 8, 10, 11, 13, 14, 16, 18, 20, 22, 23, 25, 27, 28, 30, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 56, and 58, wherein said polynucleotide encodes CDR3 of α-chain of TCR of a CDR + helper T-cell specific to a WT1 helper peptide (WT1 332 peptide) comprising SEQ ID NO: 123 or a sequence at least 90% identical to SEQ ID NO: 123.
24 . A βCDR3 peptide encoded by a polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 7, 9, 12, 15, 17, 19, 21, 24, 26, 29, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 57, and 59, wherein said polynucleotide encodes CDR3 of β-chain of TCR of a CD4 + helper T-cell specific to WT1 332 peptide.
25 . A pair of peptides encoded by a pair of polynucleotides chosen from:
SEQ ID NO:1 and SEQ ID NO:2; SEQ ID NO:3 and SEQ ID NO:4; SEQ ID NO:5 and SEQ ID NO:6; SEQ ID NO:3 and SEQ ID NO:7; SEQ ID NO:8 and SEQ ID NO:9; SEQ ID NO:10 and SEQ ID NO:12; SEQ ID NO:11 and SEQ ID NO:12; SEQ ID NO:13 and SEQ ID NO:15; SEQ ID NO:14 and SEQ ID NO:15 SEQ ID NO:16 and SEQ ID NO:17 SEQ ID NO:18 and SEQ ID NO:19 SEQ ID NO:20 and SEQ ID NO:21 SEQ ID NO:22 and SEQ ID NO:24 SEQ ID NO:23 and SEQ ID NO:24 SEQ ID NO:25 and SEQ ID NO:26 SEQ ID NO:27 and SEQ ID NO:4 SEQ ID NO:28 and SEQ ID NO:29 SEQ ID NO:30 and SEQ ID NO:32 SEQ ID NO:31 and SEQ ID NO:32 SEQ ID NO:33 and SEQ ID NO:34 SEQ ID NO:35 and SEQ ID NO:36 SEQ ID NO:37 and SEQ ID NO:38 SEQ ID NO:39 and SEQ ID NO:40 SEQ ID NO:41 and SEQ ID NO:42 SEQ ID NO:43 and SEQ ID NO:44 SEQ ID NO:45 and SEQ ID NO:46 SEQ ID NO:47 and SEQ ID NO:48 SEQ ID NO:49 and SEQ ID NO:50 SEQ ID NO:51 and SEQ ID NO:52 SEQ ID NO:53 and SEQ ID NO:54 SEQ ID NO:55 and SEQ ID NO:57 SEQ ID NO:56 and SEQ ID NO:57; or SEQ ID NO:58 and SEQ ID NO:59
wherein each of the polynucleotide sequences may be a complementary sequence or a degenerate sequence thereof.
26 . A chip comprising the peptide according to claim 23 or 24 , or the pair of the peptides according to claim 25 .Join the waitlist — get patent alerts
Track US2021070832A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.